On June 18, 2025 Imugene Limited (ASX: IMU), a clinical-stage immuno oncology company, reported it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application number 16/637,909 which protects its oncolytic virotherapy CF33-CD19 and its combination with CD19 targeting CAR T cell therapies (Press release, Imugene, JUN 18, 2025, View Source [SID1234653957]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent titled "ONCOLYTIC VIRUS EXPRESSING A CAR T CELL TARGET AND USES THEREOF" (inventors Yuman Fong, Saul Priceman, Stephen Forman, Nanhai Chen and Anthony Park from the City of Hope) protects the method of composition and method of use of Imugene’s onCARlytics technology through to August 10 2038.

Leslie Chong, Managing Director and CEO of Imugene, said:

"Imugene receiving this US patent allowance for the CF33-CD19 onCARlytics platform is a crucial step forward for our IP position, with the US being the largest healthcare market in the world. This follows patent allowance in China, an equally large cell therapy market, earlier in 2025."